Takeda Pharmaceutical (TAK) EBIT (2017 - 2026)

Takeda Pharmaceutical has reported EBIT for 10 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, EBIT fell 0.93% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 43.44% decrease from a year earlier, with the FY2026 full-year figure at $39.6 million, down 98.24% from the prior year.
• EBIT was $1.3 billion for Q2 2026 at Takeda Pharmaceutical, down from $1.3 billion in the prior quarter.
• The five-year high for EBIT was $2.9 billion in Q3 2025, with the low at -$2.7 billion in Q4 2025.
• Average EBIT over 5 years is $1.1 billion, with a median of $1.2 billion recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 268.02% in 2023, then slumped 448.93% in 2025.
• Over 5 years, EBIT stood at $1.0 billion in 2022, then slumped by 42.39% to $599.4 million in 2023, then plunged by 182.19% to -$492.7 million in 2024, then plunged by 448.93% to -$2.7 billion in 2025, then surged by 146.73% to $1.3 billion in 2026.
• The last three EBIT figures came in at $1.3 billion (Q2 2026), $1.3 billion (Q1 2026), and -$2.7 billion (Q4 2025), per Business Quant data.